AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

NovoCure Ltd Director's Dealing 2023

Mar 7, 2023

31949_dirs_2023-03-07_e5f1afa9-ea07-4927-b925-5332a6c3b903.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: NovoCure Ltd (NVCR)
CIK: 0001645113
Period of Report: 2023-03-03

Reporting Person: Shah Pritesh (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-03-03	Ordinary Shares	S	1570.00	$76.1594	Disposed	144650.00	Direct
2023-03-03	Ordinary Shares	S	2942.00	$76.1594	Disposed	141708.00	Direct
2023-03-03	Ordinary Shares	S	16909.00	$76.1594	Disposed	124799.00	Direct

Footnotes

F1: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.